Eurofins to Acquire Genetic Testing Service JSC and Enter the Clinical Genetic Testing Market in Vietnam
09 Février 2022 - 6:00PM
Business Wire
Eurofins Scientific
(“Eurofins”) (Paris:ERF), a global scientific leader in
bioanalytical testing and clinical diagnostics testing, announces
that its subsidiary, Eurofins Clinical Testing Lux Sarl, has
acquired Genetic Testing Service JSC (“Gentis”), a pioneer in
genetic testing in Vietnam. The acquisition will further enhance
Eurofins’ expansion in Asia and complement its global network of
clinical diagnostics laboratories focused on specialised and
advanced genetic testing.
Gentis is the market leader in
specialised genetic testing in Vietnam and was founded on the
principle that the technological advancements in DNA testing should
be accessible and affordable to everyone. The company provides
comprehensive specialised DNA testing services including
obstetrical genetics; genealogical DNA tests; oncology; and
COVID-19 testing services. Since its establishment 12 years ago,
Gentis has grown strongly with a reputation for outstanding quality
and has become the trusted service provider for more than 100 major
hospitals in Vietnam, as well as consumers. Gentis delivered
revenues of around EUR 10 million in 2021.
Eurofins believes that
specialised genetic testing to support critical healthcare needs
such as the detection of cancers, the detection of chromosomal
disorders during pregnancy and the prevention of genetic disorders,
is a significant growth opportunity. This acquisition will
accelerate Eurofins’ strategy to expand further into these markets
and expand its presence in South East Asia more broadly. Gentis has
a highly successful test and product menu, which will benefit from
the Eurofins network’s broad menu of genetic and genomic tests and
its access to additional markets.
“I am looking forward to
welcoming Gentis and its highly qualified and dedicated team to the
Eurofins network,” commented Dr. Gilles Martin, Eurofins CEO.
“This acquisition demonstrates our commitment to provide testing
solutions to meet critical health, wellness and genetic challenges.
It also supports our growth strategies in both Asia and advanced
specialised clinical diagnostics”
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With 55,000 staff across a network of
900 laboratories in over 50 countries, Eurofins’ companies offer a
portfolio of over 200,000 analytical methods. Eurofins Shares are
listed on Euronext Paris Stock Exchange.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220209005807/en/
For further information: Andy Nguyen ir@eurofins.com
Eurofins Scientific (EU:ERF)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Eurofins Scientific (EU:ERF)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024
Real-Time news about Eurofins Scientific SE (Euronext): 0 recent articles
Plus d'articles sur Eurofins Scient.